Tocilizumab in COVID-19: enthusiasm vs. evidence

Based on the pathophysiological characterization of COVID-19, initial studies suggested the use of tocilizumab (TCZ), a recombinant humanized monoclonal antibody of the immunoglobulin G1 class, for management of the cytokine storm witnessed in severe cases. Thus, we decided to present a case series...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeña-Huancas, Paola, León-Jiménez, Franco, Bryce-Alberti, Mayte, Portmann-Baracco, Arianna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8614601/
https://www.ncbi.nlm.nih.gov/pubmed/34747742
http://dx.doi.org/10.4103/lungindia.lungindia_766_20
Descripción
Sumario:Based on the pathophysiological characterization of COVID-19, initial studies suggested the use of tocilizumab (TCZ), a recombinant humanized monoclonal antibody of the immunoglobulin G1 class, for management of the cytokine storm witnessed in severe cases. Thus, we decided to present a case series of 18 patients with severe COVID-19 treated with TCZ at our hospital. Our results coincide with the fact that the routine use of TCZ in severe COVID-19 is not robustly supported. We believe that the efficacy and safety of this drug and other related molecules should be validated in large randomized clinical trials.

Ejemplares similares